Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

NCT06015724 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Refractory Non-Small Cell Lung Cancer

Interventions

DRUG: Daratumumab
BIOLOGICAL: KRAS vaccine
DRUG: Nivolumab

Sponsor

Georgetown University

Collaborators

[object Object]
[object Object]
[object Object]